Ann: 57% Cholesterol Reduction from NYX-PCSK9i In Vivo Study, page-35

Just to clarify, the "in Vivo" nature of the study isn't the basis of your argument against the result being of value, it would actually be that this is based on a study of the efficacy in mice? DYOR, but I believe mouse models have been good predictors for cholesterol drugs in the past - based on these result there is a good probability that this drug is effective. On a risk weighted valuation, this announcement should increase the valuation (or as noted in my earlier post) was this already priced in and the market got ahead of itself)... Noting other posts, there is also the possibility of a substantial selling out on any news/volume, so this is keeping a lid on the SP for the short term. Once that seller is out, we may see a SP uptick back to the 25c range (highest historical close). Cheers.